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asked to choose between hypothetical treatment pairs in a series of choice questions. 
Each choice alternative was deﬁned by lesion severity (redness, thickness, and texture), 
percentage of body surface area (BSA) covered by the lesions, type of treatment (oral 
agent, subcutaneous injection, or phototherapy), injection discomfort or pain (if type 
of treatment included injections), risk of serious lung infection, and monthly out-of-
pocket cost. Preference weights were estimated using mixed logit methods. Conjoint 
preference weights were used to calculate willingness-to-pay (WTP) for reductions in 
lesion severity and BSA. RESULTS: A total of 28,200 panel members were invited to 
participate in the survey. A total of 18,330 individuals responded to the invitation 
and 503 qualiﬁed to participate. A total of 419 PsO patients completed the survey; 
mean age was 54.5 years and 52% were female; 64% of patients self-reported their 
PsO severity as mild or mild-to-moderate; 12%, 12%, 7% and 3% of patients self-
reported their PsO severity as moderate, moderate-to-severe, severe, and very severe, 
respectively. Patients were willing to pay up to $486.73 per month to eliminate severe 
lesions covering 25% BSA on the arms and legs. Patients were willing to pay $429.78 
each month to eliminate severe lesions of 25% BSA on the torso. Patients were willing 
to pay $444.80 per month to eliminate moderate lesions covering 4% BSA on the 
face. CONCLUSIONS: Individuals with PsO are willing to pay more than $400 out-
of-pocket per month to reduce lesion severity and percentage of BSA covered by the 
lesions.
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OBJECTIVES: To determine impact of disease on career choices, absenteeism, and 
work loss among individuals with psoriasis (PsO). METHODS: A nationally repre-
sentative survey was conducted in Q2 2009 of PsO sufferers. Participants were ≥18 
years of age and reported their disease status as mild, moderate, and severe. Career 
choices and work productivity were assessed. Productivity was measured using the 
Work Productivity and Activity Impairment (WPAI) scale, which includes absenteeism, 
presenteeism, work productivity loss, and activity impairment. RESULTS: A total of 
1003 patients responded to the survey (mean age was 50 years, 88% were white, and 
58% were female). A higher percentage of patients with severe disease (22%) were 
disabled as compared with the moderate (15%) and mild (12%) groups. A signiﬁcantly 
higher proportion of individuals with severe disease (37%) and moderate (14%) 
reported that PsO has affected their career choice compared to those with mild disease 
(4%). Similarly, a signiﬁcantly higher percentage of individuals with severe (31%) and 
moderate (10%) disease reported that PsO affects their current career choice as com-
pared to mild disease (3%). Among the employed, on average, PsO sufferers reported 
a 4% absenteeism rate, 14% presenteeism rate, and 14% productivity loss. Activity 
impairment, regardless of employment status, was signiﬁcantly higher for the severe 
patients (54%; p < 0.05) as compared with moderate (24%) or mild (7%) sufferers. 
The severe disease group also reported signiﬁcantly higher rates of absenteeism (21%), 
presenteeism (47%), and work productivity loss (47%) than their moderate or mild 
counterparts. CONCLUSIONS: PsO is a debilitating disease which impacts multiple 
aspects of an individual’s lifestyle including career choices and physical functioning. 
Among the actively employed, moderate-to- severe PsO has a greater impact on their 
previous and current career choices as compared with patients with mild psoriasis. In 
addition, patients with severe PsO are associated with greater work loss and activity 
impairment.
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DISPARITY IN THE MANAGEMENT OF OBESITY IN AMBULATORY 
SETTING: A NAMCS 2006–07 ANALYSIS
Patel J, Mehta H, Parikh R, Abughosh S
University of Houston, Houston, TX, USA
OBJECTIVES: Disparities in anti-obesity medication use were clearly demonstrated 
by Cawley et.al. However, the most effective interventions for obesity management 
combine nutrition education, diet and exercise counseling, with pharmacotherapy. 
Thus, the objective of this study was to identify factors associated with obesity man-
agement and identify disparities in obesity management amongst adults diagnosed 
with obesity. METHODS: The study was performed using 2006 and 2007 National 
Ambulatory Medical Care Survey, a cross-sectional visit level database. Patient visits 
(>= 18 years) with an obesity diagnosis (ICD-9-CM: 278.00) were included in the 
study. Prescription of FDA approved anti-obesity medications and/or weight reduc-
tion, exercise and diet/nutrition counseling were considered as obesity management. 
Descriptive statistics and multivariate logistic regression were conducted to identify 
disparity while adjusting for age, race, sex, region, insurance status, co-morbidity and 
MSA. RESULTS: Total 113 million visits for obesity were estimated for 2006–2007. 
Obesity management was provided in 47.84% visits, of which medication was pre-
scribed in 12% of visits. Adjusted analysis showed PCP’s were more likely to provide 
obesity management (OR—1.703 CI: 1.325–2.188) than specialists. Patients from 
non-MSA region (OR—0.614 CI: 0.455–0.829), and older patients (OR—0.986 CI: 
0.978–0.994) were less likely to receive obesity management. Patient visits that were 
covered through private insurance (OR—0.317 CI: 0.166–0.606) or public insurance 
(OR—0.297 CI: 0.160–0.552), had a lesser likelihood to receive obesity management. 
Patient visits with high co-morbid conditions were more likely to receive obesity 
management (OR—1.641 CI: 1.085–2.481). CONCLUSIONS: Specialty differences 
in obesity management were identiﬁed, one in two patients diagnosed as obese did 
not receive obesity management. This suggests that, though it is a known risk factor 
for many other chronic illnesses, physicians still fail to prioritize obesity and provide 
effective management.
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URBAN GREEN SPACE AND PARK EXPENDITURES AS PREDICTORS OF 
URBAN OBESITY
Wilkins TL, Halverson J
West Virginia University, Morgantown, WV, USA
OBJECTIVES: The presence of parks and recreational areas (green spaces) in urban 
areas may facilitate increases in physical activity among urban residents and reduce 
the impact of chronic disease risk factors such as overweight and obesity. We hypoth-
esize that variable rates of obesity among major metropolitan cities in the U.S. may 
be explained by the presence of high quality green space and recreational centers. 
Speciﬁcally, that parks acres and total park expenditures will predict levels of obesity. 
We also hypothesize that the presence of recreational centers will explain variable 
levels of obesity. If the presence of quality parks in urban areas is associated with 
lower obesity prevalence, this provides evidence for policy recommendations to reduce 
the adverse effects of obesity and overweight. METHODS: City park data for the year 
2007, was linked to Behavioral Risk Factor Surveillance System SMART data from 
2007 urban responses of physical activity and obesity. The total park acreage, park 
expenditures, and recreational centers per capita were obtained from The Trust for 
Public Land. Step wise linear regression modeling was used to test our hypotheses. 
RESULTS: Overall, the model signiﬁcantly predicted Obesity Prevalence, with both 
Percent Parkland and Park Expenditures accounting for 30% of the variation in 
Obesity Prevalence [R2+0.299, F(2.47) = 10.03, p < 0.001]. Additionally, a moderate 
effect size was found for the relationship between Percent Obesity and both Percent 
Parkland and Park Expenditures (R2 = −0.34, and −0.40 respectively). Once entered 
in the second step, Recreational Centers explained no additional variance [R2 = 0.299, 
F(3.46) = 6.55, p < 0.1001]. CONCLUSIONS: Obesity prevalence is moderately 
explained by Percent Parkland and Park Expenditures. These ﬁndings have direct 
policy implications, and show that both quality and access to parks are public health 
initiatives that may be used to promote healthier communities.
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INTRAGASTRIC BALOON (IGB) FOR MORBIDLY OBESE (MOP) AND 
SUPER OBESE PATIENTS (SOP) : SYSTEMATIC REVIEW (SR) AND 
HEALTH TECHNOLOGY ASSESSMENT (HTA)
Paladini LM, Clark LGO, Clark O, Pegoretti B, Engel T, Faleiros EJM
Evidencias, Campinas, Brazil
OBJECTIVES: To compile the body of evidence and produce a HTA on IGB in 
morbidly obese (MOP) and super obese (BMI ≥ 50) patients. To evaluate the impact 
on IGB on weight loss, co-morbidities (CM), reduction of post-operatory complications 
on bariatric surgery. METHODS: We performed a SR on Medline and Cochrane 
Library among other databases, including articles published until January 2010. We 
searched “Gastric Balloon[Mesh]”, “intragastric balloon”, “Comparative Study [Pub-
lication Type]”, “Randomized Controlled Trial [Publication Type]”, “random*” e 
“systematic[sb]”. RESULTS: We found two SR without meta-analysis (MA), two SR 
with MA and two randomized controlled clinical trials (RCCT). In MOP the use of 
IGB does not improve the weight loss compared to diet (Level of Evidence 1b). There 
are no long term efﬁcacy data available and there might be a weight gain after the 
IGB is withdrawn. The risk of minor complications (gastric ulcer and abdominal pain) 
but not of major complications (intestinal obstruction and esophageal laceration) is 
greater in patients using IGB (LE 1b). For SOP there is insufﬁcient evidence to support 
that the use of IGB before bariatric surgery reduces the conversion rate from laparo-
scopic to open surgery or the intra-operatory complication risks (LE 4). There is a 
lack of evidence on the impact of IGB use on CM such as diabetes, hypertension or 
sleep apnea for both MOP and SOP. CONCLUSIONS: For MOP there is evidence 
that the use of IGB does not lead to greater weight loss compared to diet and it 
increases the risk of minor complications (LE 1b). For SOP there is insufﬁcient evidence 
of effectiveness and safety to support the use of IB as a previous step before gastric 
bypass surgery. For both, there is a lack of evidence on the impact of IGB on CM.
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FOR MUSCULOSKELETAL PAIN AT FOUR PRIMARY CARE CENTERS IN 
SWEDEN
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OBJECTIVES: Musculoskeletal pain is experienced by more than a third of the adult 
population. Alleviation of pain is an important aspect of care in these patients. The 
aim of the present study was to assess the number of NSAID prescriptions prescribed 
to patients with musculoskeletal pain during 2004–2008 at 4 primary health care 
centres in Sweden. METHODS: This retrospective longitudinal study was based on 
primary care electronic medical records review and data for patients with any ICD 
diagnosis code of musculoskeletal pain and prescription of any ATC code for NSAID, 
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selective or non-selective and weak opioids (codeine, tramadol, dextropropoxyphene) 
was extracted and analysed. RESULTS: A total of 23 456 prescriptions were analysed, 
18 187 prescribed to adults [18–64 years] and 5 269 to elderly ≥65 years of age 
[65–101 years]. The proportion of NSAID prescriptions for non-selective plus selective 
Cox-2-inhibitors (Coxibs), did not change during the 5- year period, 91.1, 91.3, 91.4, 
92 and 91.5 % of patients were prescribed an NSAID. The proportion of prescriptions 
for traditional non-selective NSAIDs increased from 83.9% to 90.3 % from year 2004 
to 2008 among adult patients and from 69.7% to 78.7% among elderly. The propor-
tion of prescriptions for Coxibs decreased between 2004 and 2008 and were pre-
scribed to 3.6 % of patients in this study in 2008. Co-prescription of gastric protective 
therapy was made in 12–20 % of prescriptions with no differences between NSAID, 
Coxibs and non-NSAID. CONCLUSIONS: In this review of NSAID prescription 
utilization among patients with a diagnosis of musculoskeletal pain shows an extensive 
use of anti-inﬂammatory agents without co-prescription of gastro-protective medica-
tion. The impact of this high utilization of NSAIDs without co-prescription of gastro-
protective agents on the risk for upper gastro-intestinal complications warrants further 
evaluation.
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IS HOSPITAL EXPERIENCE ASSOCIATED WITH BETTER IN-HOSPITAL 
OUTCOMES AMONG SICKLE CELL PATIENTS WITH ACUTE CHEST 
SYNDROME: RESULTS FROM A NATIONAL DATABASE
Kamble S, Reed SD
Duke Clinical Research Institute, Durham, NC, USA
OBJECTIVES: Acute chest syndrome (ACS) is the leading cause of death and the 
second most common cause of hospitalization in patients with sickle cell disease 
(SCD), yet it is unclear whether hospital experience (i.e., volume) is associated with 
improved clinical and resource-use outcomes. In this study, we compared inpatient 
mortality, length of stay (LOS) and total costs between high- and low-SCD volume 
hospitals treating ACS patients. METHODS: Using the 2006–2007 Nationwide Inpa-
tient Sample (NIS), we identiﬁed ACS patients based on ICD-9-CM codes 517.3 (ACS) 
or 486 (pneumonia) among discharges with SCD (Clinical Classiﬁcation Code 61). 
SCD volume represented the average number of SCD discharges from a hospital per 
year over the 2-year study period. Given that majority of patients were treated in a 
relatively small number of hospitals, the top decile was selected to represent high 
volume hospitals. We used generalized estimating equations to evaluate whether 
hospital-level SCD experience was independently associated with inpatient mortality 
(binomial distribution, logit link), LOS (negative binomial distribution, log link) and 
costs (gamma distribution, log link) between volume groups while controlling for 
gender, age, payer, number of comorbidities, and hospital characteristics, including 
rural vs. urban location, teaching status, bed size, ownership type, and hospital region. 
RESULTS: Among 6,857 ACS discharges across 688 hospitals, 4154 and 2703 were 
treated in high- and low-volume hospitals, respectively. Median age was 22 in high-
volume hospitals and 29 in low-volume hospitals. In unadjusted analyses, inpatient 
mortality (0.9% vs. 1.7%, p = 0.004), mean LOS (6.9 vs. 7.4, p = 0.005), and mean 
costs ($11,358 vs. $12,013, p = 0.077) were lower in high vs. low volume hospitals. 
After adjustment for patient and hospital characteristics, hospital volume was no 
longer signiﬁcantly associated with inpatient outcomes. CONCLUSIONS: Hospital 
volume was not signiﬁcantly associated with inpatient mortality, LOS, and total costs 
among ACS patients.
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INFLIXIMAB INDUCTION PATTERNS AND THE IMPACT ON 
MAINTENANCE THERAPY PATTERNS
Carter C1, Waters H1, Smith P2, Smith D3
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OBJECTIVES: To assess induction and maintenance infusion patterns of inﬂiximab 
(IFX) treatment in ulcerative colitis (UC) patients receiving 1, 2, or 3 induction doses. 
METHODS: A retrospective analysis of medical claims from an administrative data-
base was conducted for UC patients newly starting IFX. Patients were required to 
have age ≥18 yrs, 2 diagnosis codes for UC, IFX index date between September 1, 
2005 and January 31, 2008, and ≥ 26 months of continuous enrollment (minimum 
12 months before and 14 months after the index date). Patients with select pre-index 
inﬂammatory disorders were excluded. The analysis evaluated induction (IFX doses 
during ﬁrst 56 days post-index) and maintenance (doses >56 days and <12 months 
post-induction). Persistence during maintenance was deﬁned by a medication posses-
sion ratio (MPR) of >80%. Results were stratiﬁed by the number of induction doses 
(1, 2, or 3). RESULTS: A total of 354 UC patients were included in the analyses: 
mean (SD) age of 44 (14) yrs; 48.3% female; 62.4% received IFX in the outpatient 
ofﬁce setting. There were 27, 83, and 244 patients in the 1, 2, and 3 induction dose 
groups, respectively. The overall mean (SD) number of days during the induction 
period was 35 (14), and days increased with the number of induction doses. During 
the maintenance period, patients received an overall mean (median) of 5 (6) infusions. 
The cohort receiving 3 induction infusions had the highest percentage of patients with 
an MPR > 80%. Infusion patterns for the ﬁrst year post-induction were consistent 
with recommended prescribing information, with a median of 56 days between infu-
sions. CONCLUSIONS: The majority of IFX patients received 3 induction doses. 
Induction and maintenance infusion patterns were consistent with prescribing recom-
mendations, especially for those patients receiving 3 induction doses. These data 
support administering 3 IFX doses during induction to ensure appropriate dosing and 
optimal medication adherence during maintenance.
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MAINTENANCE INFLIXIMAB DOSING AND ADMINISTRATION 
PATTERNS IN PATIENTS WITH CROHN’S DISEASE
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1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Premier, Inc, Charlotte, NC, 
USA
OBJECTIVES: U.S. Food and Drug Administration (FDA)-approved prescribing infor-
mation recommends inﬂiximab (IFX) administration at 0, 2, 6 and every 8 weeks with 
potential dose escalation based on patient response in Crohn’s Disease (CD) patients. 
Minimal real world dosing data are available in this population. This study describes 
IFX dosing patterns in patients with CD treated in an outpatient hospital setting. 
METHODS: A retrospective longitudinal analysis using the Premier PerspectiveTM 
Database, a U.S.-based hospital database, was conducted. Inclusion criteria were an 
outpatient hospital discharge CD diagnosis between July 1, 2000 and March 31, 2008, 
IFX-naïve (received no IFX in the prior 180 days), and ≥ 3 IFX doses within ≤56 days 
of the index infusion. Exclusion criteria included patients with other selected inﬂam-
matory diseases. Treatment duration was deﬁned as the time between the index and 
last IFX dose. Hospital outpatient dosing schedules were analyzed for the 4th through 
15th IFX dose, representing the ﬁrst two years of IFX maintenance treatment. 
RESULTS: A total of 1439 IFX-treated patients with CD were identiﬁed. Mean (SD) 
age was 42.8 (15.4) years; 59% were female. Mean (SD) treatment duration was 415 
(425) days. Patients received a mean (SD) of 8.4 (7.5) IFX administrations. Mean (SD) 
index IFX dose was 429 (152) mg. During the initial two years of maintenance IFX 
administration, the highest observed mean IFX dose represented a 10% increase 
during the maintenance period and a 13% increase compared to the index IFX dose. 
Median time between administrations was 56 days for all maintenance infusions. 
CONCLUSIONS: The mean IFX dose remained between 439 and up to 483 mg 
throughout the maintenance treatment. Administration schedule was consistent with 
FDA-approved prescribing information. These data suggest that IFX dosing patterns 
in CD patients remain relatively stable with minimal dose escalation occurring when 
administered in real world outpatient hospital settings.
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US COST EFFECTIVENESS ANALYSIS OF PRIMARY PROPHYLAXIS 
VERSUS ON-DEMAND TREATMENT IN HEMOPHILIA: DESIGN AND 
RATIONALE OF A COMPREHENSIVE MODEL
Boer R1, Lalla A1, Mathew P2, Preblick R3, Pocoski J3
1Cerner LifeSciences, Beverly Hills, CA, USA, 2University of New Mexico, Albuquerque, NM, 
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OBJECTIVES: To present the design of a lifetime Markov model that compares the 
cost-effectiveness of primary prophylaxis versus on-demand treatment with recombi-
nant factor VIII among children with severe hemophilia A. METHODS: Prophylactic 
infusions of rFVIII-FS have been shown to reduce the frequency of bleeding episodes 
and the risk of joint damage in children with hemophilia A with no pre-existing joint 
damage. Clinical studies have shown signiﬁcant improvement in outcomes with the 
use of prophylactic treatment, as well as apparent gains in health-related quality of 
life. However, recombinant clotting factors are also associated with relatively high 
cost. Using a lifetime Markov model, the cost-effectiveness of primary prophylaxis 
treatment was compared to on-demand treatment. This model is among the few that 
model long-term cost and effectiveness and is unique in that it takes into account the 
probability of inhibitor development, use of central venous access device (CVAD), and 
total bleeding risk including CNS and joint bleeds. Prophylactic treatment is assumed 
to be from birth until 16 years of age. Built in the model were also 5 health states: 
being alive, surgery, inhibitor development, disability and deceased. SUMMARY: 
From this model, cost-effectiveness estimations can be made for patients receiving 
on-demand treatment versus primary prophylaxis. Cost-effectiveness can vary by the 
frequencies of events between treatment arms, age where prophylaxis begins and ends, 
dose/frequency of factor VIII, cost of medications and key hospital-related events, and 
the probability of achieving speciﬁed clinical endpoints. CONCLUSIONS: The 
strengths and distinguishing characteristics of this model versus previously published 
hemophilia prophylaxis models include: long-term cost and effectiveness, probability 
of inhibitor development, use of CVAD, and CNS bleeds. There are a few study limita-
tions related to the lack of data for model assumptions. Obtaining stronger evidence 
for these parameters may substantiate or potentially improve the model results.
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USING PATIENT FOCUS GROUPS TO INFORM ECONOMIC MODELING: 
EXPERIENCE FROM A HEMOPHILIA PATIENT FOCUS GROUP
Lalla A1, Boer R1, Pocoski J2, Dean B1
1Cerner LifeSciences, Beverly Hills, CA, USA, 2Bayer HealthCare Pharmaceuticals, Inc., 
Wayne, NJ, USA
BACKGROUND: Decision modeling is commonly used to assess the cost-utility of 
drugs or technologies. For a real-world application, models should include aspects of 
the disease relevant to the patient. In recent years, patient focus groups have been used 
to help deﬁne health utility values. METHODS: Hemophilia patients attending the 
National Hemophilia Foundation’s 61st Annual Meeting were invited to participate 
in a focus group to inform the development of a decision model, evaluating prophy-
